Genitourinary Cancer

Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPC

May 02, 2022

The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.